ΌΡΤΙΜΛ

OPTIMA at a glance – Revolutionising oncology

Overview

The OPTIMA project is a multi-stakeholder-led consortium with the vision of providing access to cutting-edge **personalised treatments** and innovative therapies for patients with lung, breast and prostate cancer.

The primary objective is to design and deliver an interoperable, GDPR-compliant European real-world **oncology data platform**, tailored to the needs of clinicians and patients to enhance shared decision-making.

Impact

Improved patient outcomes through tailored treatments and novel therapies.

Enhanced clinical decision-making based on robust evidence and guideline adherence.

In-depth **understanding of cancer** outcomes and patient well-being via advanced analytics.

Establishment of rigorous **data protection** measures for patients' personal data.

Objectives

Real-world Data Integration: Gather and harmonise large-scale structured and unstructured real-world datasets, combining information from diverse sources.

Al-guided Decision Support: Develop a secure, sustainable platform incorporating Al-driven decision support tools aligned with the latest clinical practice guidelines.

Guideline Prioritisation: Focus on prostate, breast, and lung cancer to create a scalable and regularly updated guideline decision-support tool.

Advanced Analytics and Al Models: Utilise Al and advanced analytics to generate new knowledge and insights for better cancer care.

Key Components

Al-guided Decision Support Tool: A sophisticated tool aiding clinicians in making evidence-based decisions using up-to-date guidelines and patient-specific data.

Data Integration and Harmonisation: Robust processes to collate and standardise real-world datasets from multiple sources, ensuring data integrity and reliability.

Ethical and Legal Compliance: Adherence to all legal and ethical standards concerning patient data privacy and research conduct.





OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

ΟΡΤΙΜΛ

OPTIMA Overview – Setting new standards in Cancer Research

Collaboration

The OPTIMA project fosters collaboration among medical professionals, researchers, patients and patient advocates, technology experts and the pharmaceutical industry.

An **inclusive** and **sustainable** approach underpins the consortium's efforts to drive impactful research outcomes.

Implementation

The OPTIMA platform will be deployed in clinical settings, **providing real-world support** to clinicians and patients.

Continuous evaluation and optimisation will ensure platform efficacy and technical robustness.



Data Privacy

Patient data confidentiality and privacy will be rigorously maintained, adhering to **stringent data protection** rules and regulations.

Conclusion

The OPTIMA project is a collaborative endeavour poised to **revolutionise cancer care** through advanced data-driven approaches and **Al-guided decision support.**

By integrating **real-world data**, prioritising guideline adherence, and leveraging cutting-edge technologies, the project aims to significantly impact **personalised cancer treatments** and **shared decision-making**, ultimately leading to improved patient outcomes and well-being.





etpia

OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.